Palonosetron intravenous - Dr. Reddys Laboratories
Alternative Names: Palonosetron hydrochloridee intravenous - Dr. ReddyLatest Information Update: 22 Jan 2019
At a glance
- Originator Dr Reddys Laboratories
- Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
Most Recent Events
- 22 Jan 2019 Discontinued - Registered for Chemotherapy-induced nausea and vomiting (Prevention) in USA, prior January 2019 (IV)
- 22 Jan 2019 Discontinued - Registered for Postoperative nausea and vomiting (Prevention) in USA, prior January 2019 (IV)
- 02 Nov 2012 The US FDA issues tentative approval to palonosetron (0.075 mg/1.5mL and 0.25 mg/5mL) injection for Postoperative nausea and vomiting and Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)